Development of a Quantifiable Symptom Assessment Tool for Patients with Chronic Bronchitis: The Chronic Bronchitis Symptoms Assessment Scale

Au, David H.; Blough, David K.; Kirchdoerfer, Leonard; Weiss, Kevin B.; Udris, Edmunds M.; Sullivan, Sean D.

doi:10.1081/copd-57580

Cited by 13 publications

(9 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ideally, we would have used an additional cough-specific questionnaire. However, such questionnaires have not been specifically developed for, nor tested in COPD patients [11-15]. We used the SGRQ as the reference standard.…”

Section: Methodsmentioning

confidence: 99%

“…One study found that only a small part (2%) of the variance in the scores of the St. George's Respiratory Questionnaire (SGRQ), a disease-specific health status questionnaire is explained by cough [2]. Several cough-specific health status questionnaires have been developed and validated in the general population presenting with cough but not necessarily with COPD [11-15]. Of these questionnaires only the Leicester Cough Questionnaire (LCQ) [16] is available in Dutch [17].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The validity and precision of the leicester cough questionnaire in COPD patients with chronic cough

Berkhof

Boom

Hertog

et al. 2012

Health Qual Life Outcomes

View full text Add to dashboard Cite

BackgroundA validated instrument to assess the effects of chronic cough on health status in patients with chronic obstructive pulmonary disease (COPD) is currently not available. The Leicester Cough Questionnaire (LCQ) is a cough-specific health status questionnaire which is originally validated for a population of general patients presenting with chronic cough. We examined the psychometric performance of the LCQ in patients with COPD and chronic productive cough.MethodsConcurrent validity, internal consistency, reproducibility and responsiveness were determined. The St. George's Respiratory Questionnaire (SGRQ) and the Short Form-36 (SF-36) were used as external criteria. Questionnaires were completed at the start of the study. After 2 and 12 weeks the LCQ was repeated, together with a global rating of change.ResultsIn total 54 patients were included. Concurrent validity analysis showed significant correlations between corresponding domains of the LCQ and the SGRQ (rs -0.31 to -0.60). Corresponding domains of the LCQ and the SF-36 showed weaker correlations (rs 0.04 to 0.41). Internal consistency was adequate for two of the three domains (Cronbach's α 0.74 - 0.86). Test-retest reliability in stable patients was high (intraclass correlation coefficients 0.79 - 0.93). The mean difference after two weeks was 0.73 (± 1.75). Responsiveness analysis indicated that the LCQ was able to detect changes after 12 weeks.ConclusionThe LCQ is a valid, reliable, responsive instrument to measure health status in COPD patients with chronic productive cough.Trial RegistrationClinicalTrials.gov: NCT01071161

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The validity and precision of the leicester cough questionnaire in COPD patients with chronic cough

Berkhof

Boom

Hertog

et al. 2012

Health Qual Life Outcomes

View full text Add to dashboard Cite

show abstract

“…As secondary clinical outcomes, we evaluated changes in the three domains of the SGRQ, the Chronic Bronchitis Symptoms Assessment Scale (CBSAS), and the Short Form-36 Health Survey (SF-36). 16 , 17 We assessed lung function with postbronchodilator spirometry, systemic inflammation with serum C-reactive protein levels, and systemic oxidative stress with plasma 8-isoprostane levels. 18 We further assessed oxidative stress and biochemical efficacy of NAC, by measuring changes in thiol redox couples, GSH/GSH disulfide (GSSG) and cysteine/cystine (Cys/CySS) in plasma.…”

Section: Methodsmentioning

confidence: 99%

High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial

Johnson

McEvoy

Naqvi

et al. 2016

COPD

View full text Add to dashboard Cite

BackgroundClinical outcomes are worse in patients with COPD and chronic bronchitis. N-acetylcysteine (NAC) is commonly prescribed for such patients but with uncertain clinical benefits. We postulated that oral NAC, at much larger doses than those ordinarily prescribed, would improve clinical outcomes in a subset of patients with COPD and chronic bronchitis.ObjectiveThe aim of this study was to determine whether very high-dose NAC would improve respiratory health status in patients with COPD and chronic bronchitis.MethodsPatients with COPD and chronic bronchitis were enrolled in a randomized, controlled, double-blinded trial. Patients received oral NAC (1,800 mg) or matching placebo twice daily for 8 weeks in addition to their usual respiratory medications. The primary outcome, respiratory health status, was assessed by changes in the St George’s Respiratory Questionnaire. The effects of NAC on lung function and circulating markers of oxidative stress and inflammation were also evaluated.ResultsWe terminated the study prematurely because new external information suggested the possibility of a safety issue. Of the planned 130 patients, 51 were randomized and 45 (22 in the placebo arm and 23 in the NAC arm) completed the study. There was no statistically significant difference between changes in the St George’s Respiratory Questionnaire total score, comparing NAC to placebo (adjusted mean difference, 0.1 U; 95% CI, −7.8 to 8.18 U; P=0.97). There were also no significant NAC-related improvements in any of the secondary outcomes.ConclusionIn this 8-week trial, we were unable to show any clinical benefit from a very high dose of NAC in patients with COPD and chronic bronchitis.

show abstract

“…This instrument was developed to measure symptom and functional state in daily clinical practice. The most recent symptom questionnaire is the Chronic Bronchitis Symptoms Assessment Scale; this symptom questionnaire uses 16 items to capture symptoms in patients with COPD (83). The instrument demonstrated strong internal reliability (overall Cronbach's ␣ of 0.91), as well as statistically significant and moderate to strong associations with spirometry.…”

Section: Table 3 Overview Of Selected Instruments That Assess Signs mentioning

confidence: 99%

Patient-reported Outcomes in Cystic Fibrosis

Goss¹,

Quittner²

2007

Proceedings of the American Thoracic Society

116

107

View full text Add to dashboard Cite

Over the past 20 years, there has been tremendous progress in the area of patient-reported outcomes (PROs). A PRO instrument is defined as any measure of a patient's health status that is elicited directly from the patient and assesses how the patient "feels or functions with respect to his or her health condition." The advances seen in clinical research regarding PROs has been mirrored in research in cystic fibrosis (CF). A large number of instruments have been used for both therapeutic and nontherapeutic clinical research for many chronic conditions. This review will summarize a history of the development of PROs and how PROs are viewed by the U.S. Food and Drug Administration. We will then review the current state of the art of patient-reported outcomes in CF, specifically addressing the evaluation of different PRO instruments in terms of their reliability and validity. Finally, we will delineate further areas for development of PROs in CF. We believe that the future of CF research will incorporate a more diverse selection of PRO outcome measures; these outcome measures ultimately may be incorporated into clinical care to standardize symptom assessment and provide information regarding the need for specific clinical interventions to improve the quality of care delivered to these patients.

show abstract

Development of a Quantifiable Symptom Assessment Tool for Patients with Chronic Bronchitis: The Chronic Bronchitis Symptoms Assessment Scale

Cited by 13 publications

References 18 publications

The validity and precision of the leicester cough questionnaire in COPD patients with chronic cough

The validity and precision of the leicester cough questionnaire in COPD patients with chronic cough

High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial

Patient-reported Outcomes in Cystic Fibrosis

Contact Info

Product

Resources

About